(Q37158935)

18 August 2017

Sneaky side effects and ineffectiveness of an immunotherapy with ipilimumab in a case of metastatic melanoma (English)

1 reference

18 August 2017

0 references

1 reference

1 reference

Nathalie Krecké

1

1 reference

18 August 2017

Anna Zimmer

2

1 reference

18 August 2017

Bettina Friesenhahn-Ochs

3

1 reference

18 August 2017

Cornelia S L Müller

4

1 reference

18 August 2017

Thomas Vogt

5

1 reference

18 August 2017

Claudia Pföhler

6

1 reference

18 August 2017

1 January 2016

1 reference

18 August 2017

Dermato-endocrinology

1 reference

18 August 2017

8

1 reference

18 August 2017

1

1 reference

18 August 2017

e1199307

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

18 August 2017

start time

1 January 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977105

Checkpoint Blockade for the Treatment of Advanced Melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977105

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977105

Ipilimumab-induced Ocular and Orbital Inflammation--A Case Series and Review of the Literature

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977105

Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977105

Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977105

Immunotherapy-induced leukoderma from treatment of melanoma with IL-2: a case report and a review of the literature

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977105

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977105

Immunologic functions as prognostic indicators in melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977105

Autoimmunity and treatment outcome in melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977105

Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977105

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977105

Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977105

Orbital myositis associated with ipilimumab

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977105

Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977105

A case report of orbital inflammatory syndrome secondary to ipilimumab

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977105

Ipilimumab-induced orbital inflammation resembling Graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression

20 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977105

Autoimmune inflammatory myopathy after treatment with ipilimumab

20 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4977105

Association between autoimmune disease and cutaneous melanoma with regard to melanoma prognosis

20 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27574531

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Inflammatory Orbitopathy Associated With Ipilimumab

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27574531

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1080/19381980.2016.1199307

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

27574531

1 reference